Axial Biotherapeutics announced a $440,000 grant from the Michael J. Fox Foundation for Parkinson’s Research to support its efforts to develop a model that can mimic the nervous system of the gastrointestinal tract, and help in evaluating potential Parkinson’s disease treatments. Though Parkinson’s is primarily considered a neurodegenerative disorder,…

The U.S. Food and Drug Administration (FDA) will review Acadia Pharmaceutical’s application asking that Nuplazid (pimavanserin) also be approved to treat hallucinations and delusions associated with various forms of dementia-related psychosis, the company announced. The supplemental new drug application (sNDA) was granted standard review status, and the…

Lower than usual activity in a complex that recycles proteins in cells — called the proteosome — leads to an age-related buildup of protein aggregates in the brains of fish, similar to that seen in neurodegenerative diseases such as Parkinson’s, a study reported. Low proteasome activity…

Seelos Therapeutics has begun a preclinical study in rodents to test a gene therapy approach to deliver its investigational candidate SLS-007, a potential treatment for Parkinson’s disease. Results are expected by late this year or early 2021. One hallmark of Parkinson’s disease progression is the formation of…

Subtle changes in the levels of Alzheimer’s disease biomarkers in patients at the earlier stages of Parkinson’s disease may provide clues about the evolution of their motor and cognitive functions, a study says. The study, “Evolution of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in Early…

Multiple administrations of Affitope PD01A, an investigational vaccine for Parkinson’s disease, elicit a safe and sustained immune response against alpha-synuclein — a protein involved in the development of Parkinson’s — in patients at the early stages of the disease, according to results from a Phase 1…

Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms…

Researchers have developed short gene promoters — structures that act like switches to turn on genes — that may boost the effectiveness of gene therapies targeting the central nervous system. These promoters allow for the delivery of larger genes into the central nervous system while keeping them active for…

Nitrome Biosciences has raised $38 million in Series A financing to advance its lead program toward clinical trials for Parkinson’s disease (PD) and other age-related disorders. “This financing will enable Nitrome to advance our mission of impacting the lives of patients with neurodegenerative and other age-related diseases,” said…

Mutations in a gene called ATP10B may increase the risk of developing Parkinson’s disease, a study has found. When mutated, ATP10B is no longer able to provide instructions to make a functional protein that is necessary to transport a fatty substance — known…